AGC Group (AGC Inc.; formerly Asahi Glass Co., Ltd.) is a global manufacturer of glass, chemicals, and advanced materials founded in 1907 and headquartered in Tokyo, Japan. The company serves construction, automotive, electronics, and life-science markets, with manufacturing and R&D operations across Asia, Europe, and the Americas.
Within the chemical industry, AGC produces chlor-alkali products, fluorochemicals and fluoropolymers (such as PTFE and ETFE), fluoroelastomers, ion-exchange membranes, and specialty materials for semiconductor and electronic applications, alongside ceramics and other industrial materials. The group also participates in downstream derivatives in selected regions and provides biopharmaceutical contract development and manufacturing services through AGC Biologics.
Also known as Asahi Glass Co., Asahi Glass Co., Ltd., AGC Inc., and AGC.
chemXplore tracks 5 projects involving AGC, of which 2 are active.
AGC's role on them: Owner, Investor / Financier, Operator, Developer, Technology licensor, and Technology / equipment supplier.
1 new construction and 1 revamp / retrofit.
1 of the active projects carry no start-up date yet.
Licensors and offtakers are recorded on all 2 of them For subscribers
Yokohama technical center began cell therapy process development in July 2025 and has been awarded multiple exosome and T‑cell projects, including a program transferred from Milan.
Hybrid furnace to cut CO₂ from flat glass production; construction starts Jan 2027, production H2 2027; co-funded by the EU ETS Innovation Fund.
End-to-end CDMO support for NTX-083 completed — manufacturing process established and IND CMC documentation prepared ahead of planned US clinical trials in 2026.
Japan's first closed-loop scheme turns demolition window glass into cullet for clear float glass; 81 t used in flat glass, 149 t collected, estimated CO₂ cut 49 t.
Deal covers commercial manufacturing of multiple biopharmaceuticals using new Yokohama site; revenue expected at several tens of billions of yen; GMP services targeted for 2027.
Transfer covers a 50.72% holding in APK, a producer of polyurethane waterproofing and flooring materials; closing expected around Dec 2026 pending approvals.
Adds US sterile fill-finish, device assembly and packaging to create an integrated drug substance–drug product supply for clinical programs.
A June 2026 pilot will collect discarded windshields from repairs, separate laminated glass and use recovered cullet as feedstock for architectural flat glass production.
